Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens

Eun Hye Cho, Hee Jae Huh, Dong Joon Song, Seung Heon Lee, Chang Ki Kim, So Youn Shin, Chang Seok Ki, Byung Woo Jhun, Seong Mi Moon, O. Jung Kwon, Won Jung Koh, Nam Yong Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In this study, we aimed to retrospectively investigate and compare the drug susceptibility patterns of two major Mycobacterium abscessus complex (MABC) species; M. abscessus and M. massiliense. A total of 546 MABC respiratory isolates (277 M. abscessus and 269 M. massiliense) from 2011 to 2016 were analyzed in this study. We estimated minimum inhibitory concentrations (MICs) using the broth microdilution method, and we calculated MIC 50 and MIC 90 values from the MIC distribution. Both M. abscessus and M. massiliense were highly susceptible to amikacin and linezolid. For M. abscessus, the proportions of inducible and acquired resistance to clarithromycin were 68.6% and 12.3%, respectively. Only 15.2% of M. abscessus remained susceptible at day 14. On the other hand, none of the M. massiliense showed inducible resistance and 6.3% showed acquired resistance to clarithromycin. A total of 92.6% of the M. massiliense remained susceptible at day 14. The resistance rate of M. abscessus to moxifloxacin (90.3%) was significantly higher than that of M. massiliense (83.3%; p = 0.016). These susceptibility differences may explain the divergent treatment outcomes between patients with pulmonary disease caused by these two species.

Original languageEnglish
Pages (from-to)107-111
Number of pages5
JournalDiagnostic Microbiology and Infectious Disease
Volume93
Issue number2
DOIs
Publication statusPublished - 2019 Feb 1
Externally publishedYes

Fingerprint

Microbial Sensitivity Tests
Mycobacterium
Linezolid
Clarithromycin
Pharmaceutical Preparations
Amikacin
Lung Diseases
Inhibitory Concentration 50

Keywords

  • Drug susceptibility test
  • Mycobacterium abscessus
  • Mycobacterium massiliense
  • Nontuberculous mycobacteria

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. / Cho, Eun Hye; Huh, Hee Jae; Song, Dong Joon; Lee, Seung Heon; Kim, Chang Ki; Shin, So Youn; Ki, Chang Seok; Jhun, Byung Woo; Moon, Seong Mi; Kwon, O. Jung; Koh, Won Jung; Lee, Nam Yong.

In: Diagnostic Microbiology and Infectious Disease, Vol. 93, No. 2, 01.02.2019, p. 107-111.

Research output: Contribution to journalArticle

Cho, Eun Hye ; Huh, Hee Jae ; Song, Dong Joon ; Lee, Seung Heon ; Kim, Chang Ki ; Shin, So Youn ; Ki, Chang Seok ; Jhun, Byung Woo ; Moon, Seong Mi ; Kwon, O. Jung ; Koh, Won Jung ; Lee, Nam Yong. / Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. In: Diagnostic Microbiology and Infectious Disease. 2019 ; Vol. 93, No. 2. pp. 107-111.
@article{01a05d27ba8b484f885d3b4a1ed5511a,
title = "Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens",
abstract = "In this study, we aimed to retrospectively investigate and compare the drug susceptibility patterns of two major Mycobacterium abscessus complex (MABC) species; M. abscessus and M. massiliense. A total of 546 MABC respiratory isolates (277 M. abscessus and 269 M. massiliense) from 2011 to 2016 were analyzed in this study. We estimated minimum inhibitory concentrations (MICs) using the broth microdilution method, and we calculated MIC 50 and MIC 90 values from the MIC distribution. Both M. abscessus and M. massiliense were highly susceptible to amikacin and linezolid. For M. abscessus, the proportions of inducible and acquired resistance to clarithromycin were 68.6{\%} and 12.3{\%}, respectively. Only 15.2{\%} of M. abscessus remained susceptible at day 14. On the other hand, none of the M. massiliense showed inducible resistance and 6.3{\%} showed acquired resistance to clarithromycin. A total of 92.6{\%} of the M. massiliense remained susceptible at day 14. The resistance rate of M. abscessus to moxifloxacin (90.3{\%}) was significantly higher than that of M. massiliense (83.3{\%}; p = 0.016). These susceptibility differences may explain the divergent treatment outcomes between patients with pulmonary disease caused by these two species.",
keywords = "Drug susceptibility test, Mycobacterium abscessus, Mycobacterium massiliense, Nontuberculous mycobacteria",
author = "Cho, {Eun Hye} and Huh, {Hee Jae} and Song, {Dong Joon} and Lee, {Seung Heon} and Kim, {Chang Ki} and Shin, {So Youn} and Ki, {Chang Seok} and Jhun, {Byung Woo} and Moon, {Seong Mi} and Kwon, {O. Jung} and Koh, {Won Jung} and Lee, {Nam Yong}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.diagmicrobio.2018.08.008",
language = "English",
volume = "93",
pages = "107--111",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens

AU - Cho, Eun Hye

AU - Huh, Hee Jae

AU - Song, Dong Joon

AU - Lee, Seung Heon

AU - Kim, Chang Ki

AU - Shin, So Youn

AU - Ki, Chang Seok

AU - Jhun, Byung Woo

AU - Moon, Seong Mi

AU - Kwon, O. Jung

AU - Koh, Won Jung

AU - Lee, Nam Yong

PY - 2019/2/1

Y1 - 2019/2/1

N2 - In this study, we aimed to retrospectively investigate and compare the drug susceptibility patterns of two major Mycobacterium abscessus complex (MABC) species; M. abscessus and M. massiliense. A total of 546 MABC respiratory isolates (277 M. abscessus and 269 M. massiliense) from 2011 to 2016 were analyzed in this study. We estimated minimum inhibitory concentrations (MICs) using the broth microdilution method, and we calculated MIC 50 and MIC 90 values from the MIC distribution. Both M. abscessus and M. massiliense were highly susceptible to amikacin and linezolid. For M. abscessus, the proportions of inducible and acquired resistance to clarithromycin were 68.6% and 12.3%, respectively. Only 15.2% of M. abscessus remained susceptible at day 14. On the other hand, none of the M. massiliense showed inducible resistance and 6.3% showed acquired resistance to clarithromycin. A total of 92.6% of the M. massiliense remained susceptible at day 14. The resistance rate of M. abscessus to moxifloxacin (90.3%) was significantly higher than that of M. massiliense (83.3%; p = 0.016). These susceptibility differences may explain the divergent treatment outcomes between patients with pulmonary disease caused by these two species.

AB - In this study, we aimed to retrospectively investigate and compare the drug susceptibility patterns of two major Mycobacterium abscessus complex (MABC) species; M. abscessus and M. massiliense. A total of 546 MABC respiratory isolates (277 M. abscessus and 269 M. massiliense) from 2011 to 2016 were analyzed in this study. We estimated minimum inhibitory concentrations (MICs) using the broth microdilution method, and we calculated MIC 50 and MIC 90 values from the MIC distribution. Both M. abscessus and M. massiliense were highly susceptible to amikacin and linezolid. For M. abscessus, the proportions of inducible and acquired resistance to clarithromycin were 68.6% and 12.3%, respectively. Only 15.2% of M. abscessus remained susceptible at day 14. On the other hand, none of the M. massiliense showed inducible resistance and 6.3% showed acquired resistance to clarithromycin. A total of 92.6% of the M. massiliense remained susceptible at day 14. The resistance rate of M. abscessus to moxifloxacin (90.3%) was significantly higher than that of M. massiliense (83.3%; p = 0.016). These susceptibility differences may explain the divergent treatment outcomes between patients with pulmonary disease caused by these two species.

KW - Drug susceptibility test

KW - Mycobacterium abscessus

KW - Mycobacterium massiliense

KW - Nontuberculous mycobacteria

UR - http://www.scopus.com/inward/record.url?scp=85053677899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053677899&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2018.08.008

DO - 10.1016/j.diagmicrobio.2018.08.008

M3 - Article

C2 - 30236529

AN - SCOPUS:85053677899

VL - 93

SP - 107

EP - 111

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 2

ER -